QTREX Quantum Ltd 6-K, filed Aug 10, 2021
QTREX Quantum Ltd. (QTEX)
About this 6-K
QTREX Quantum Ltd filed this 6-K on August 10, 2021.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of: August 2021
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
CONTENTS
On August 10, 2021, Inspira Technologies Oxy B.H.N. Ltd., or the registrant, issued a press release titled “Inspira Technologies Expands Board of Directors to Accelerate Company’s Go-to-Market Efforts,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Inspira Technologies Oxy B.H.N. Ltd. | |||
| Date: August 10, 2021 | By: | /s/ Dagi Ben-Noon | |
| Name: | Dagi Ben-Noon | ||
| Title: | Chief Executive Officer | ||
2
Exhibit 99.1
Inspira Technologies Expands Board of Directors to
Accelerate Company’s Go-to-Market Efforts
CPA Lior Amit to join the board of directors
Ra’anana, Israel / August 10, 2021/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN, IINNW) (the “Company”), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies, today announced the appointment of Lior Amit, CPA, to the Company’s board of directors.
Mr. Amit has extensive business and go-to-market experience to further support Inspira’s planned future deployment and market penetration of the Augmented Respiration Technology (ART) system.
For more than 17 years, Mr. Amit served as the CFO of the BBR Saatchi & Saatchi advertising group in Israel, playing a vital role in the growth of the organization. Today, Mr. Amit serves as a director of leading start-ups and publicly traded companies, such as ScoutCam Inc. (OTCQB:SCTC), which develops and manufactures customized visual solutions by offering micro cameras and supplementary technologies, the Israeli Credit Insurance Company (ICIC) and NIRPLEX Ltd., a corporation of agencies specializing in exclusive representation of international companies and producers for the Israeli market.
Lior Amit, CPA,
stated: "Inspira is a highly dynamic and active company. The innovative ART technology
addresses a huge unmet need as it aims to treat early-stage patients with cost-effective,
extracorporeal technology while they are awake. It is an honor to join Inspira on this very exciting journey.
"
Dagi Ben-Noon, Inspira's CEO, stated: "Inspira welcomes
Mr. Amit to its board of directors. Mr. Amit has extensive business experience that can contribute to the Company's
efforts in its go-to-market
strategy, which includes exploring partnership opportunities with leading medical device companies, manufacturers and distributors."
Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical technology company in the respiratory treatment arena. The Company has developed a breakthrough Augmented Respiration Technology, which it believes will elevate and stabilize patient oxygen saturation levels. The Company’s ART technology potentially allows patients to remain awake during treatment while minimizing the use of the highly invasive, risky and costly mechanical ventilation systems that require medically induced coma. The Company’s product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA).
For more information, please visit our corporate website:
https://inspira-technologies.com/
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward-looking statements when it mentions that Lior Amit has extensive business experience that can contribute to the Company's efforts in its go-to-market strategy . These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Registration Statement on Form F-1 filed with the SEC, which is available on the SEC’s website, www.sec.gov.
For more details:
Miri Segal, Investor Relations, MS-IR LLC
+917-607-8654, msegal@ms-ir.com